GNH USA

Europe — EMA

Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

GNH USA supplies Mydriasert (Phenylephrine Hydrochloride/Tropicamide), a mydriatic agent for diagnostic eye examinations and intra‑ocular procedures.

Phenylephrine Hydrochloride, Tropicamide

Request sourcing

1
Pack/s

What is Phenylephrine Hydrochloride, Tropicamide?

Phenylephrine Hydrochloride/Tropicamide, the active ingredient in Mydriasert, is a mydriatic agent presented as an ophthalmic solution for ocular use. It induces pupil dilation to facilitate ophthalmic examinations and intra‑ocular procedures in patients requiring a clear view of the interior eye. Mydriasert is manufactured for the EU market and complies with international quality standards.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Phenylephrine Hydrochloride, Tropicamide used for?

Mydriasert, a combination of phenylephrine hydrochloride and tropicamide, is used in ophthalmology to achieve pharmacologic mydriasis.

- Diagnostic eye examinations: provides pupil dilation for thorough fundus evaluation. - Intra‑ocular surgery: facilitates access during cataract extraction or retinal procedures. - Laser therapy: enables adequate pupil size for laser photocoagulation. - Glaucoma assessment: allows visualization of angle structures during gonioscopy.

What are the side effects of Phenylephrine Hydrochloride, Tropicamide?

Mydriasert may cause a range of ocular and systemic reactions.

Common Side Effects: - Transient ocular discomfort or stinging sensation. - Redness of the conjunctiva. - Mild headache. - Temporary blurred vision. - Light sensitivity (photophobia).

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Systemic hypertension or blood pressure spikes. - Cardiac arrhythmias. - Severe allergic reaction (anaphylaxis). - Persistent cycloplegia beyond the expected duration.

What precautions apply to Phenylephrine Hydrochloride, Tropicamide?

Prior to using Mydriasert, consider the following safety measures.

- Assess intra‑ocular pressure: avoid in patients with narrow‑angle glaucoma. - Screen for cardiovascular disease: phenylephrine may elevate blood pressure. - Check for hypersensitivity: discontinue if allergic reactions occur. - Use with caution in children: safety data are limited. - Store at ambient temperature: keep in the original container, protect from light and moisture.

What does Phenylephrine Hydrochloride, Tropicamide interact with?

Mydriasert can interact with other medications; monitor patients accordingly.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis due to additive vasoconstriction. - Tricyclic antidepressants: may increase systemic blood pressure effects.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may blunt systemic cardiovascular responses. - Other mydriatic agents: can lead to excessive pupil dilation. - Anticholinergic drugs: may enhance cycloplegic effects.

Frequently asked questions

What is Mydriasert used for?+
Mydriasert is an ophthalmic solution containing phenylephrine hydrochloride and tropicamide that is used to induce pupil dilation (mydriasis) for diagnostic eye examinations, intra‑ocular surgeries, and laser procedures. The drug provides a clear view of the interior structures of the eye, facilitating accurate assessment and treatment.
How does phenylephrine hydrochloride work in Mydriasert?+
Phenylephrine hydrochloride is an alpha‑1 adrenergic agonist. It binds to alpha‑1 receptors on the radial iris dilator muscle, causing the muscle to contract. This contraction pulls the iris outward, widening the pupil and contributing to the overall mydriatic effect when combined with tropicamide.
What is the usual dose of Mydriasert?+
The specific dosage and administration schedule for Mydriasert are determined by the prescribing eye care professional based on the patient’s condition, age, and the intended procedure. Clinicians select the appropriate number of drops and timing to achieve the desired level of pupil dilation.
Is Mydriasert safe to use during pregnancy or breastfeeding?+
Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate the individual situation and discuss possible alternatives when necessary.
How do I order Mydriasert from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity of Mydriasert. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.
How does Mydriasert compare with other mydriatic agents?+
Mydriasert combines phenylephrine, an alpha‑1 agonist, with tropicamide, a muscarinic antagonist, offering rapid and sustained dilation. Compared with single‑agent preparations, this combination often achieves a broader pupil size more quickly, reducing the need for multiple drops and improving procedural efficiency.
What are the storage and handling requirements for Mydriasert?+
Mydriasert should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture to maintain stability. Do not freeze the product, and keep the container tightly closed when not in use.
How is Mydriasert administered?+
Mydriasert is applied topically to the eye as a drop. The prescribing clinician determines the number of drops and timing, typically instilling the solution into the conjunctival sac of the target eye(s) a few minutes before the examination or procedure.
What are the most serious risks associated with Mydriasert?+
Serious risks include acute angle‑closure glaucoma, significant systemic hypertension, and rare cardiac arrhythmias. Patients with narrow‑angle glaucoma or uncontrolled cardiovascular disease should be evaluated carefully before use, and any signs of severe adverse reactions require immediate medical attention.
Who should not use Mydriasert?+
Mydriasert should be avoided in individuals with known hypersensitivity to phenylephrine, tropicamide, or any excipients in the formulation. It is also contraindicated in patients with narrow‑angle or acute angle‑closure glaucoma, and caution is advised for those with severe cardiovascular disorders.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Phenylephrine Hydrochloride, Tropicamide
Route
Ocular Use
Manufacturer
Laboratoires Thea
Origin
EU

Related products

Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU